Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus efficacy in recurrent pregnancy loss
IRCT20250527065938N1Phase 3Completed
- Sponsor
- No. 971941913114، Yakhchal Street، Dr. Shariati Street, Tehran, Iran.
- Start
- Jun 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of tacrolimus in recurrent miscarriage (RPL), sponsored by No. 971941913114، Yakhchal Street، Dr. Shariati Street, Tehran, Iran. Primary endpoints: Pregnancy confirmation by serum beta-hCG and Live birth. Started Jun 2025; status: completed.
02
Drugs
tacrolimus
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on IRCT20250527065938N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250527065938N1.